Overview: This Phase 2 trial evaluates pasireotide (Signifor), a long-acting somatostatin analog, as maintenance therapy following standard treatment for synovial sarcoma and desmoplastic small round cell tumor. Somatostatin receptors SSTR2, SSTR3, and SSTR5 are frequently overexpressed in both tumor types, providing the rationale for targeting them after initial chemotherapy, surgery, or radiation. Participants receive monthly pasireotide injections for up to four years. The trial is designed to assess whether this targeted maintenance approach can delay or prevent disease relapse.